TWP
HAE icon

TFO Wealth Partners’s Haemonetics HAE Stock Holding History

TFO Wealth Partners’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2
Closed -$171 – 352
2024
Q1 		$171 Hold
2
– – ﹤0.01% 528
2023
Q4 		$171 Hold
2
– – ﹤0.01% 685
2023
Q3 		$170 Hold
2
– – ﹤0.01% 877
2023
Q2 		$170 Hold
2
– – ﹤0.01% 551
2023
Q1 		$166 Sell
2
-36
-95% -$2.91K ﹤0.01% 529
2022
Q4 		$1.97K Buy
+38
New +$3.05K ﹤0.01% 257

Other funds holding HAE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TFO Wealth Partners's HAE Position: Q2 2024 in Review

TFO Wealth Partners sold out of Haemonetics (HAE) in Q2 2024, closing a stake of 2 shares — an estimated $171 sold.

TFO Wealth Partners first reported a position in HAE in Q4 2022 and held it in 6 quarters. The position peaked at $1.97K in Q4 2022. 317 funds tracked by Wall St. Rank hold HAE as of Q2 2024.

  • TFO Wealth Partners reported no remaining Haemonetics position as of Q2 2024 after selling out during the quarter.
  • TFO Wealth Partners sold 2 Haemonetics shares in Q2 2024, an estimated $171.
  • TFO Wealth Partners first reported a position in Haemonetics in Q4 2022 and held it in 6 quarters.
  • TFO Wealth Partners's Haemonetics position peaked at $1.97K in Q4 2022.
  • 317 funds tracked by Wall St. Rank held Haemonetics as of Q2 2024.

Based on TFO Wealth Partners's 13F filing for Q2 2024, filed 15 Aug 2024.